Delving into the Latest Updates on Glycadia, Inc. with Synapse

Overview

Basic Info

Introduction

Glycadia's research is centered around the impact of circulating glycated proteins on the development of diabetic complications such as kidney and eye problems. The company is working on creating drugs that inhibit the excessive nonenzymatic glycation of important proteins to reduce the negative effects of these blood-borne factors on cell signaling pathways and molecular mediators.

Tags

Endocrinology and Metabolic Disease

Nervous System Diseases

Cardiovascular Diseases

Small molecule drug

Antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	4
Nervous System Diseases	3

Top 5 Drug Type	Count

Small molecule drug	3
Antibody	2

Top 5 Target	Count

APOB x Cholesterol	1
COX-1(Cyclooxygenase-1)	1

BACKGROUNDThe nonenzymatic condensation of glucose with albumin results in the formation of albumin modified by Amadori glucose adducts, the principal form in which glycated albumin exists in vivo.SCOPE OF REVIEWThis review focuses on (a) the utility of measurement of Amadori-modified glycated albumin (AGA) as a biomarker in diabetes, where elevated levels attend the hyperglycemic state; (b) the role of AGA as a causal factor in the pathogenesis of complications of diabetes; (c) effects on transport properties; and (d) structural and functional consequences of the modification of albumin by Amadori glucose adducts. It does not discuss counterparts with respect to Advanced Glycation Endproducts (AGE), which may be found in other publications.MAJOR CONCLUSIONSNonenzymatic glycation of albumin, which is increased in diabetes, has clinical relevance and pathophysiologic importance, with ramifications for the management of this disease, the development of its complications, and the transport of endogenous and exogenous ligands.GENERAL SIGNIFICANCEAppreciation of the manifold consequences of AGA has afforded new avenues for assessing clinical management of diabetes, awareness of the impact of nonenzymatic glycation on albumin biology, insights into the pathogenesis of vascular complications of diabetes, and avenues of investigation of and intervention strategies for these complications. This article is part of a Special Issue on albumin. This article is part of a Special Issue entitled Serum Albumin.

01 Jan 2010·Journal of Diabetes & Metabolism

Rate of Formation of Glycated Albumin Revisited and Clinical Implications

Author: Cohen, Margo P. ; Shea, Elizabeth ; Hud, Elizabeth

Background: Albumin modified by Amadori glucose adducts contributes to the pathogenesis of complications of diabetes and reducing its formation ameliorates their development, underscoring the need for accurate information on the rate of formation of this biol. active glycated protein.However, this subject has not been examined in over two decades, and there is reason to question data in older reports.Methods: The present study used nonradioactive and nonreductive techniques to examine the rate of formation of glycated albumin and compare it to that of glycoHb, using a sensitive and specific immunoassay for measurement of the stable glucose adduct formed after incubation of serum, plasma and purified albumin with glucose.Results and Conclusions: We report that the rate of formation of glycated albumin parallels that of glycoHb at approx. 0.005-0.008 percent per mM glucose per day, refuting values from the older literature and providing clin. relevant information concerning levels of glycated albumin in diabetes and of treatment directed at reducing its formation.

01 Jan 2010·American Journal of NephrologyQ3 · MEDICINE

Anti-Glycation and Anti-Albuminuric Effects of GLY-230 in Human Diabetes

Q3 · MEDICINE

Article

Author: Laurence Kennedy ; Luigi F Meneghini ; Margo P. Cohen ; Maria Pilar Solano ; Margaret Lo

Background/Aims: Inhibiting nonenzymatic glycation with GLY-230 lowers glycated albumin without affecting hyperglycemia and ameliorates renal dysfunction in the db/db mouse, but the effects of this compound in man have not been assessed. We report results from the first clinical trial in patients with diabetes of this new glycation inhibitor. Methods: 21 diabetic men were randomly assigned to receive a total dose of 250, 500 or 750 mg of GLY-230 or placebo (1:1:1:1.2 ratio) daily for 14 days to evaluate safety and the effect of drug on plasma concentrations of glycated albumin and on urinary albumin. Results: GLY-230 dose-responsively decreased glycated albumin in all participants, in whom HbA1c did not change. Among participants exhibiting microalbuminuria at baseline, mean albumin excretion significantly decreased in patients receiving GLY-230 (µg albumin/mg creatinine = 61.4 ± 15.8 and 29.8 ± 10.4 at baseline and completion, respectively; p = 0.001), but not placebo. There were no serious adverse events or laboratory abnormalities, and all safety parameters remained within normal limits. Conclusions: This first-in-diabetic man study indicates that GLY-230 lowers glycated albumin and that this decrease is associated with a reduction in urine albumin excretion in patients with preexisting microalbuminuria. These data encourage further evaluation of GLY-230 in diabetic renal dysfunction.

100 Deals associated with Glycadia, Inc.

Login to view more data

100 Translational Medicine associated with Glycadia, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

3

1

Phase 2 Clinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

GLY-230 ( COX-1 )	Diabetic Nephropathies More	Phase 2
CAP-22 ( APOB x Cholesterol )	Diabetes Complications More	Clinical
ES12	Vascular Diseases More	Preclinical
A717	Diabetic Retinopathy More	Preclinical
GLY-220	Diabetic Angiopathies More	Preclinical